Back to top

Bull of the Day

We are maintaining our positive bias on Transcept Pharmaceuticals (TSPT). We believe the stock is significantly undervalued at this level, and that the market is overly pessimistic on the ability of management to address the issues raised in the FDA's complete response letter from last October.

From what we have seen, management has an excellent plan to answer the questions brought up by the agency and we think everything could be ready to re-file by October 2010. That puts an action date in April 2011.

With nearly $90 million in cash still on the books at year-end 2009 and a market value of only $105 million, Transcept offers enormous upside once Intermezzo is finally approved by the FDA.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
STRATTEC SE… STRT 80.24 +3.00%
PATTERSON-U… PTEN 34.54 +2.98%